Damia Tormo

Damia Tormo has a diverse work experience spanning various roles and companies. In 2013, they founded Artax Biopharma Inc and served as the CEO and Co-founder until 2019. They also founded Syngoi Therapeutics in 2021. In addition to their entrepreneurial ventures, Damia Tormo has held director positions at Aleta Biotherapeutics Inc, Integra Therapeutics, Minoryx Therapeutics, and Tyris tx. They have also served as a General Partner at COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A and as a Member of the Board of Directors at ALGENEX S.L. Furthermore, Damia Tormo has been involved with organizations such as Fundación Columbus and Radioterapia de Protones (Quirón). Overall, their work experience showcases their expertise in biopharmaceuticals, genetic treatments, venture capital, and medical solutions.

Damia Tormo began their education at the University of Valencia, where they obtained a Master of Science (MS) degree in Biology from 1999 to 2004. They then attended the Bonn-Rhein-Sieg University of Applied Sciences in 2003 and 2004, earning a Bachelor of Science (BS) degree in Biological Sciences. Continuing their education, Tormo pursued a PhD in Molecular Genetics and Immunology from The University of Bonn, where they studied from 2004 to 2007. After completing their doctorate, Tormo attended IE Business School in 2009 and 2010, earning a Master's degree in Biotechnology management. In 2010, they also took a course for Biotech Executives at Genoma España. Their education concluded with a brief attendance at the University of Cambridge in 2011, where they participated in the Judge Business School, CfEL, Centre for Entrepreneurial Learning, focusing on Entrepreneurship.